Home › Essential Thrombocythemia › Kansas
Essential Thrombocythemia clinical trials in Kansas
3 studies for Essential Thrombocythemia are looking for participants at sites in Kansas.
A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs)
- University of Kansas Clinical Research Center, Fairway
- University of Kansas Cancer Center, Kansas City
- University of Kansas Hospital-Indian Creek Campus, Overland Park
- and 1 more
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 30, 2026 · NCT06661915A Phase 3 Study of INCA033989 Versus Best Available Therapy in Participants With Essential Thrombocythemia
- The University of Kansas Cancer Center, Westwood
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Sep 14, 2026 · NCT07623200A Study to Evaluate INCA033989 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasms
- The University of Kansas Cancer Center, Westwood
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Apr 17, 2026 · NCT06034002From ClinicalTrials.gov, data retrieved Oct 2, 2026. Each study sets its own eligibility; the study team decides who can join.